Increased parietal and occipital lobe gyrification predicts conversion to syndromal psychosis in a clinical high-risk cohort.

Clinical high-risk (CHR) Inferior parietal Lateral occipital Local gyrification index (lGI) Neurodevelopmental Psychosis

Journal

Schizophrenia research
ISSN: 1573-2509
Titre abrégé: Schizophr Res
Pays: Netherlands
ID NLM: 8804207

Informations de publication

Date de publication:
05 2023
Historique:
received: 23 07 2021
revised: 15 02 2023
accepted: 12 03 2023
medline: 15 5 2023
pubmed: 13 4 2023
entrez: 12 4 2023
Statut: ppublish

Résumé

Local gyrification index (lGI), indicative of the degree of cortical folding is a proxy marker for early cortical neurodevelopmental abnormalities. We studied the difference in lGI between those who do and do not convert to psychosis (non-converters) in a clinical high-risk (CHR) cohort, and whether lGI predicts conversion to psychosis. Seventy-two CHR participants with attenuated positive symptom syndrome were followed up for two years. The difference in baseline whole-brain lGI was examined on the T1-weighted MRIs between, i)CHR (N = 72) and healthy controls (N = 19), ii)Converters to psychosis (N = 24) and non-converters (N = 48), adjusting for age and sex, on Freesurfer-6.0. The significant cluster obtained in the converters versus non-converters comparison was registered as a region of interest to individual images of all 72 participants and lGI values were extracted from this region. A cox proportional hazards model was applied with these values to study whether lGI predicts conversion to psychosis. lGI was not different between CHR and healthy controls. lGI was increased in converters in the right-sided inferior parietal and lateral occipital areas (corrected cluster-wise-p-value = 0.009, cohen's f = 0.42) compared to non-converters, which significantly increased the risk of onset of psychosis (p = 0.029, hazard ratio = 1.471). Increased gyrification in the right-sided inferior parietal and lateral occipital area differentiates converters to psychosis in CHR, significantly increasing the risk of conversion to psychosis. This measure may reflect underlying traits in parts of the brain that develop earliest in-utero (parietal and occipital), conferring a heightened vulnerability to convert to syndromal psychosis subsequently.

Sections du résumé

BACKGROUND
Local gyrification index (lGI), indicative of the degree of cortical folding is a proxy marker for early cortical neurodevelopmental abnormalities. We studied the difference in lGI between those who do and do not convert to psychosis (non-converters) in a clinical high-risk (CHR) cohort, and whether lGI predicts conversion to psychosis.
METHODS
Seventy-two CHR participants with attenuated positive symptom syndrome were followed up for two years. The difference in baseline whole-brain lGI was examined on the T1-weighted MRIs between, i)CHR (N = 72) and healthy controls (N = 19), ii)Converters to psychosis (N = 24) and non-converters (N = 48), adjusting for age and sex, on Freesurfer-6.0. The significant cluster obtained in the converters versus non-converters comparison was registered as a region of interest to individual images of all 72 participants and lGI values were extracted from this region. A cox proportional hazards model was applied with these values to study whether lGI predicts conversion to psychosis.
RESULTS
lGI was not different between CHR and healthy controls. lGI was increased in converters in the right-sided inferior parietal and lateral occipital areas (corrected cluster-wise-p-value = 0.009, cohen's f = 0.42) compared to non-converters, which significantly increased the risk of onset of psychosis (p = 0.029, hazard ratio = 1.471).
CONCLUSIONS
Increased gyrification in the right-sided inferior parietal and lateral occipital area differentiates converters to psychosis in CHR, significantly increasing the risk of conversion to psychosis. This measure may reflect underlying traits in parts of the brain that develop earliest in-utero (parietal and occipital), conferring a heightened vulnerability to convert to syndromal psychosis subsequently.

Identifiants

pubmed: 37043842
pii: S0920-9964(23)00121-4
doi: 10.1016/j.schres.2023.03.027
pii:
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

246-255

Subventions

Organisme : NIMH NIH HHS
ID : R01 MH093398
Pays : United States

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest FAP is an advisor for and has equity in Imij Technologies. RRG receives research funding from BioAdvantex Pharma, Genentech, and Allergan. SAS has equity in or serves on the scientific advisory board of Denali Therapeutics, MeiraGTx, and Imij Technologies. Both FAP and SAS have a patent related to generating cerebral blood volume from which no royalties are received. JAL receives grant and/or research support or serves on the advisory board of but receives no direct financial compensation or salary support from, Alkermes, Boehringer Ingelheim, Intra-Cellular Therapies, Eli Lilly and Company/Denovo Biopharma, Pierre Fabre, Taisho Pharmaceutical R&D, Inc., and Teva and has patent payments from Repligen and royalty payments from Little, Brown (Shrinks: The Untold Story of Psychiatry). GB receives royalty payments from Prometheus Books (The New Evil: Under- standing the Emergence of Modern Violent Crime). RB, JF and HCS report no biomedical financial interests or potential conflicts of interest.

Auteurs

Rakshathi Basavaraju (R)

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, USA.

Jeanelle France (J)

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, USA.

Hannah C Sigmon (HC)

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, USA.

Ragy R Girgis (RR)

Department of Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University Medical Center, USA.

Gary Brucato (G)

Department of Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University Medical Center, USA.

Jeffrey A Lieberman (JA)

Department of Psychiatry, College of Physicians and Surgeons, New York State Psychiatric Institute, Columbia University Medical Center, USA.

Scott A Small (SA)

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, USA.

Frank A Provenzano (FA)

Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University Medical Center, USA. Electronic address: fap2005@columbia.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH